Kiniksa Pharmaceuticals International, plc
Every calculator, already run for KNSA
Open the full toolkit →You have the numbers on KNSA. Get the argument.
A written report on which of these readings actually decide the outcome for Kiniksa Pharmaceuticals International, plc, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering KNSAAnalyst Price Target Disagreement for Kiniksa Pharmaceuticals International, plc
Wall Street's bull case implies +42% from the current price; the bear case implies +14%. Analysts are relatively aligned on KNSA's range.
Ownership & short interest
Insider Trading Activity for KNSA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Phar…
KNSA — frequently asked
Is KNSA a buy right now?
Wall Street's consensus rating on Kiniksa Pharmaceuticals International, plc is none across 8 analysts, with a mean price target of $98.00 (+29% vs. the current $76.10). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is KNSA overvalued?
KNSA trades at 75.3x trailing earnings, against a DCF fair value of $101 per share. The current price implies 2% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is KNSA's next earnings date?
Kiniksa Pharmaceuticals International, plc is next scheduled to report earnings around Oct 27, 2026. A full KNSA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Kiniksa Pharmaceuticals International, plc?
Analysts covering Kiniksa Pharmaceuticals International, plc (KNSA) range from a bear-case target of $87.00 to a bull-case high of $108.00, with a mean consensus target of $98.00 across 8 analysts. The spread of $21.00 (28% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Kiniksa Pharmaceuticals International, plc against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Kiniksa Pharmaceuticals International, plc
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KNSA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Kiniksa Pharmaceuticals International, plc, in minutes. 3 free reports included with every account — no credit card required.